Philip A J Crosbie
Overview
Explore the profile of Philip A J Crosbie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goodley P, Balata H, Robbins H, Booton R, Sperrin M, Crosbie P
BMJ Oncol
. 2025 Mar;
3(1):e000560.
PMID: 40046247
Objective: Risk prediction models are used to determine eligibility for targeted lung cancer screening. However, prospective data regarding model performance in this setting are limited. Here we report the performance...
2.
Ahmad S, Pesola F, Crosbie P, Gabe R, Hancock N, Kennedy M, et al.
Lung Cancer
. 2025 Jan;
200:108086.
PMID: 39879786
Introduction: Lung cancer screening saves lives by detecting cancers early, but continued adherence to screening rounds is required for participants to experience the maximum clinical benefit. Here we describe factors...
3.
Almatrafi A, Gabe R, Beeken R, Neal R, Clegg A, Best K, et al.
J Med Screen
. 2025 Jan;
9691413251315087.
PMID: 39865893
Background: Low-dose computed tomography screening reduces lung cancer-specific mortality in high-risk individuals. Lung cancer risk factors overlap with comorbid diseases, highlighting the significance of frailty and comorbidities for lung cancer...
4.
Gabe R, Crosbie P, Vulkan D, Bailey H, Baldwin D, Bradley C, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39709114
Introduction: Low-dose computed tomography screening for lung cancer reduces lung cancer mortality, but there is a lack of international consensus regarding the optimal eligibility criteria for screening. The Yorkshire Lung...
5.
Jensen S, Moore D, Surani A, Crosbie P, Rosenfeld N, Rintoul R
J Thorac Oncol
. 2024 Dec;
19(12):e101-e102.
PMID: 39645301
No abstract available.
6.
Khan S, Hatton N, Tough D, Rintoul R, Pepper C, Calman L, et al.
BJC Rep
. 2024 Nov;
1(1):21.
PMID: 39516402
Introduction: Lung cancer in never smokers (LCINS) accounts for 15% of lung cancers diagnosed in the UK, making it the 8th most common cancer. There are few robust studies specific...
7.
Stewart G, Godoy A, Farquhar F, Kitt J, Cartledge J, Kimuli M, et al.
Eur Urol
. 2024 Sep;
PMID: 39271419
Background And Objective: The Yorkshire Kidney Screening Trial (YKST) assessed the feasibility of adding abdominal noncontrast computed tomography (NCCT) to lung cancer screening to screen for kidney cancer and other...
8.
Jensen S, Moore D, Surani A, Crosbie P, Rosenfeld N, Rintoul R
J Thorac Oncol
. 2024 Jul;
19(10):1415-1426.
PMID: 39059487
As a result of an increased focus on early detection including lung cancer screening, combined with more curative treatment options, the 5-year survival rates for lung cancer are improving. Welcome...
9.
McInnerney D, Simmonds I, Hancock N, Rogerson S, Lindop J, Gabe R, et al.
BMJ Open
. 2024 Jul;
14(7):e084577.
PMID: 38986555
Introduction: Lung cancer is the most common cause of cancer death globally. In 2022 the UK National Screening Committee recommended the implementation of a national targeted lung cancer screening programme,...
10.
Usher-Smith J, Masson G, Godoy A, Burge S, Kitt J, Farquhar F, et al.
PLoS One
. 2024 Jul;
19(7):e0300313.
PMID: 38950010
Objectives: The Yorkshire Kidney Screening Trial (YKST) is a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal malignancies to community-based CT screening...